Regular and Young Investigator Award Abstracts最新文献_第3页

452 Efficacy and safety of camrelizumab combination therapy in patients with recurrent or metastatic cervical and endometrial carcinoma: a retrospective study camrelizumab联合治疗复发或转移性宫颈癌和子宫内膜癌的疗效和安全性:一项回顾性研究

Regular and Young Investigator Award Abstracts Pub Date : 2022-11-01 DOI: 10.1136/jitc-2022-sitc2022.0452

S. Niu, Zhao-hui Fang, Xiangshan Chen, Siyang Liu, Ge Jin, Yunfeng Guo, Qianying Zhang, Hong Liu

{"title":"452 Efficacy and safety of camrelizumab combination therapy in patients with recurrent or metastatic cervical and endometrial carcinoma: a retrospective study","authors":"S. Niu, Zhao-hui Fang, Xiangshan Chen, Siyang Liu, Ge Jin, Yunfeng Guo, Qianying Zhang, Hong Liu","doi":"10.1136/jitc-2022-sitc2022.0452","DOIUrl":"https://doi.org/10.1136/jitc-2022-sitc2022.0452","url":null,"abstract":"Background Recurrent or metastatic cervical and endometrial carcinoma is largely an incurable disease due to lack of effec-tive therapies. New treatment strategies are needed to provide long-term anti-tumor responses. Blocking the interaction between PD-1 and its ligands is a promising treatment strat-egy, and has previously shown encouraging antitumor activity in cervical and endometrial carcinoma. Camrelizumab is a humanised anti-programmed death-1 (anti PD-1) antibody. Therefore, this study aimed to assess the efficacy and safety of camrelizumab combination therapy in patients with recurrent or metastatic cervical and endometrial carcinoma. Methods Patients (pts) with recurrent or metastatic cervical and endometrial carcinoma were enrolled. Eligible patients were aged 30 – 70 years with an Eastern Cooperative Oncology Group performance status of 0-2. Pts received camrelizumab (200mg iv d1 q2w) with concurrent chemoradiotherapy (CRT)/radiation/chemotherapy. Paclitaxel and carboplatin are delivered with 175mg/m2 and AUC=5, respectively, d1, q3w for 6-8 cycles. Pts received radiation with external-beam radiotherapy 45~50.4Gy/25~28f, lymph node 60Gy/25~30f 5 times/week, brachytherapy 28~30Gy/4-5f. The primary end-point was objective response (ORR). The secondary endpoints included disease control rate (DCR), median progression-free survival (mPFS) and safety. Results 37 pts were enrolled from Sept. 2019 to Apr. 2022. 36 patients were evaluated for efficacy, the ORR and DCR was 53% (19/36) and 83% (30/36","PeriodicalId":398566,"journal":{"name":"Regular and Young Investigator Award Abstracts","volume":"38 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126072753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

1112 PARP inhibition increases in the suppressive capacity of tumor-associated Tregs in a BRCA1-deficient model of ovarian cancer 1112在brca1缺失的卵巢癌模型中，PARP抑制肿瘤相关Tregs的抑制能力增加

Regular and Young Investigator Award Abstracts Pub Date : 2022-11-01 DOI: 10.1136/jitc-2022-sitc2022.1112

D. Falcon, I. Kinjyo, S. Adams

引用次数: 0

725 Phase I safety and preliminary efficacy of PM8002 in subjects with advanced solid tumors, a bispecific antibody targeting PD-L1 and VEGF-A PM8002是一种靶向PD-L1和VEGF-A的双特异性抗体，在晚期实体肿瘤患者中的I期安全性和初步有效性

Regular and Young Investigator Award Abstracts Pub Date : 2022-11-01 DOI: 10.1136/jitc-2022-sitc2022.0725

Ye Guo, S. Luo, Yanru Qin, Yongmei Yin, Gui-Chen Li, Jingfen Wang, Yongsheng Li, Jun Guo, Feng-ju Zhang, Yi Huang, H. Luo, D. Lv, Cheng Ying, Chunyan Wang, C. Chou, Chundan Gong, Ruixia Chang, Jing Liu, Guoqiang Hu

引用次数: 0

271 B cell primed CD8 T cells generate similar phenotype, function and anti-tumor responses to DC primed CD8 T cells 271 B细胞启动的CD8 T细胞与DC细胞启动的CD8 T细胞产生相似的表型、功能和抗肿瘤反应

Regular and Young Investigator Award Abstracts Pub Date : 2022-11-01 DOI: 10.1136/jitc-2022-sitc2022.0271

Ichwaku Rastogi, D. McNeel

引用次数: 0

372 agenT-797, a native allogeneic “off-the-shelf” invariant natural killer T (iNKT) cell therapy product improves effector functions within the tumor microenvironment 372 agenT-797是一种天然同种异体“现成的”不变自然杀伤T (iNKT)细胞治疗产品，可改善肿瘤微环境中的效应物功能

Regular and Young Investigator Award Abstracts Pub Date : 2022-11-01 DOI: 10.1136/jitc-2022-sitc2022.0372

Sapana Pokharel, J. Chamberland, Yu Qin, D. Moskowitz, Reed Masakayan, X. Michelet, D. Chand, B. Yigit, M. Dijk

{"title":"372 agenT-797, a native allogeneic “off-the-shelf” invariant natural killer T (iNKT) cell therapy product improves effector functions within the tumor microenvironment","authors":"Sapana Pokharel, J. Chamberland, Yu Qin, D. Moskowitz, Reed Masakayan, X. Michelet, D. Chand, B. Yigit, M. Dijk","doi":"10.1136/jitc-2022-sitc2022.0372","DOIUrl":"https://doi.org/10.1136/jitc-2022-sitc2022.0372","url":null,"abstract":"Background T cell exhaustion is a common phenomenon that occurs in the tumor microenvironment (TME) due to pro-longed exposure of T cells to tumor antigen. This is in part governed by the suppressive microenvironment created by myeloid cells. Immune checkpoint inhibitors have shown promising outcomes in clinical trials treating patients with solid cancer. However, not all patients with cancer respond to checkpoint therapy, demonstrating an unmet need to optimize the current approaches including cell therapies and combina-tion strategies. We show here that agenT-797 can reinvigorate exhausted T-cells and differentially target myeloid cells Methods We developed a multi-platform to evaluate interac-tion of agenT-797 with exhausted antigen-specific T cells and myeloid cells. Briefly, we transduced pan T cells with an NY-ESO-1 specific TCR and co-cultured them for multiple rounds with melanoma cell line, A375 that endogenously expresses HLA-A*02:01 and NY-ESO-1 antigen. Killing capacity, cyto-kine profile and phenotype of T cells were analyzed at each round of antigen exposure. We observed progressively reduced activity with each successive round. To assess whether addition of agenT-797 rescues functional impairment of partially exhausted T cells, we performed co-culture experiments of agenT-797 (or conditioned media) with T cells and A375 cells and monitored tumor cell killing and activation of T cells. In addition, we generated M1 and M2 macrophages and DCs and co-cultured them with agenT-797 to monitor activation and killing.","PeriodicalId":398566,"journal":{"name":"Regular and Young Investigator Award Abstracts","volume":"384 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123390783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

465 Synergistic approach to overcome the solid tumor microenvironment of mesothelioma with natural killer cell-focused immunotherapy 465自然杀伤细胞聚焦免疫疗法克服间皮瘤实体肿瘤微环境的协同方法

Regular and Young Investigator Award Abstracts Pub Date : 2022-11-01 DOI: 10.1136/jitc-2022-sitc2022.0465

Pippa Kennedy, Q. Kile, B. Jacobson, B. Ettestad, Sarah Miller, Jeffrey S. Miller, Manish Patel, M. Felices

{"title":"465 Synergistic approach to overcome the solid tumor microenvironment of mesothelioma with natural killer cell-focused immunotherapy","authors":"Pippa Kennedy, Q. Kile, B. Jacobson, B. Ettestad, Sarah Miller, Jeffrey S. Miller, Manish Patel, M. Felices","doi":"10.1136/jitc-2022-sitc2022.0465","DOIUrl":"https://doi.org/10.1136/jitc-2022-sitc2022.0465","url":null,"abstract":"Background Mesothelioma is a rare, but aggressive cancer that occurs in cells that surround internal organs. Immune check-point inhibitors (ICI) have been approved for the treatment of mesothelioma (nivolumab, ipilimumab and pembrolizumab), but currently approved strategies do not make use of natural killer (NK) cell mediated antibody-dependent cellular cytotoxicity (ADCC) of mesothelioma cells. We hypothesized that combining IL-15 treatment with an anti-PDL1 ICI that drives ADCC will enhance NK cell control of mesothelioma and lead to more robust immune control of the disease. Methods In vitro assays challenged NK cells with three pleural mesothelioma lines, H2373, H2461 and H2596 and four peritoneal mesothelioma lines, ROB, HAY and Flow cytometry was used to assess degranulation and cytokine pro-duction by NK cells co-cultured with mesothelioma cells in short-term assays (5 hours). The tumor cells were treated overnight with IFN g to mimic the inflammatory tumor microenvironment. Natural cytotoxicity was compared with ICI that do not drive ADCC (pembrolizumab), ICI that drive ADCC (avelumab) and IL-15, alone or in combination. Live cell imaging was used to track mesothelioma survival in three dimensional spheroids over 5 days when treated with NK cells and these drugs. NK cell natural cytotoxicity, H2373 H2596 sensitive. resistant","PeriodicalId":398566,"journal":{"name":"Regular and Young Investigator Award Abstracts","volume":"39 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123421746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

478 Real-world outcomes in patients with penile squamous cell carcinoma (pSCC) receiving immune checkpoint inhibitors (ICI) 478例阴茎鳞状细胞癌(pSCC)患者接受免疫检查点抑制剂(ICI)的真实结局

Regular and Young Investigator Award Abstracts Pub Date : 2022-11-01 DOI: 10.1136/jitc-2022-sitc2022.0478

T. Zhuang, S. Goyal, Jacqueline T. Brown, B. Carthon, Omer Kucuk, G. McClintock, L. Yantorni, M. Bilen, V. Master, B. Nazha

引用次数: 0

541 mregDC/T helper niches enable local reactivation of CD8 T cells upon PD-1 blockade 541 mregDC/T辅助小生境能够在PD-1阻断时局部激活CD8 T细胞

Regular and Young Investigator Award Abstracts Pub Date : 2022-11-01 DOI: 10.1136/jitc-2022-sitc2022.0541

Assaf Magen, Pauline Hamon, N. Fiaschi, R. Deering, S. Gnjatic, M. Schwartz, T. Marron, G. Thurston, A. Kamphorst, M. Merad

引用次数: 0

1299 Predicting CD8+ cell density and tumor-immune phenotypes in non-small-cell lung cancer (NSCLC) from standard H&E slides using deep learning (DL) 使用深度学习(DL)从标准H&E载玻片预测非小细胞肺癌(NSCLC)的CD8+细胞密度和肿瘤免疫表型

Regular and Young Investigator Award Abstracts Pub Date : 2022-11-01 DOI: 10.1136/jitc-2022-sitc2022.1299

D. Soong, Becky Arbiv, E. Markovits, Alon Groisman, Y. Shachaf, Tomer Dicker, Yoni Yedidia, Hisham K Hamadeh, K. Sasser, Gali Golan, Brandon Higgs, S. Couto, O. Zelichov

{"title":"1299 Predicting CD8+ cell density and tumor-immune phenotypes in non-small-cell lung cancer (NSCLC) from standard H&E slides using deep learning (DL)","authors":"D. Soong, Becky Arbiv, E. Markovits, Alon Groisman, Y. Shachaf, Tomer Dicker, Yoni Yedidia, Hisham K Hamadeh, K. Sasser, Gali Golan, Brandon Higgs, S. Couto, O. Zelichov","doi":"10.1136/jitc-2022-sitc2022.1299","DOIUrl":"https://doi.org/10.1136/jitc-2022-sitc2022.1299","url":null,"abstract":"Background Tumor infiltrated lymphocytes (TIL), namely CD8 + TILs play a major role in antitumor immunity and tumor cell eradication. High-density infiltration of CD8+ cells in the tumor, in contrast to CD8+ cell excluded regions, is associ-ated with improved prognosis and response to immunotherapy in multiple cancer types, however, CD8 evaluations require IHC staining, often not performed routinely in clinical practice. Here, we used DL to predict CD8+ cell density and immune phenotypes from standard H&E slides. Methods 188 pairs of H&E slide and a sequential CD8 stained slide from 103 patients with metastatic NSCLC were procured. DL models were trained to classify tumor cells, lymphocytes, fibroblasts, and tumor versus stromal areas on H&E, as well as positivity of CD8 per cell by IHC. 354 spatial features were calculated from the H&E slides and CD8+ density in the whole tumor region from IHC slides. A training (n=143) and test (n=45) cohort was created and linear regression modeling predicted CD8 density from H&E features. Two board certified pathologists classified IHC slides into immune phenotypes: inflamed, desert and excluded, based on CD8 density (table 1) and a multinomial logistic regression model was train to predicet these phenotypes from the H&E images.","PeriodicalId":398566,"journal":{"name":"Regular and Young Investigator Award Abstracts","volume":"30 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125304643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

1334 AVA-ADR-001 supresses tumor growth and induces anti-tumor immunity by selectively inhibiting ADAR1 p150 1334 AVA-ADR-001通过选择性抑制ADAR1 p150抑制肿瘤生长，诱导抗肿瘤免疫

Regular and Young Investigator Award Abstracts Pub Date : 2022-11-01 DOI: 10.1136/jitc-2022-sitc2022.1334

Arun B Papaiah, Avijit Goswami, S. Goyal, Kawaljit Singh, Princy Khurana, Aditya Kulkarni

引用次数: 0